Answers are grounded in this paper and cite their sources.
Case report reveals immune checkpoint inhibitors may cause epididymo-orchitis in a patient with renal cancer, indicating caution in treatment.
Immune checkpoint inhibitors (ICI) have revolutionised pharmacological chemotherapy for various malignant neoplasms. The side effects of ICIs are still being fully understood. We present a case of a male patient in his mid-50s with a history of metastatic renal cell carcinoma ultimately diagnosed with bilateral epididymo-orchitis (EO) following pembrolizumab maintenance treatment. Our report adds to the three identified cases of EO linked to immune checkpoint inhibitors. This rarely reported association should serve as a cautionary tale for future clinicians about the possible side effects of these immune-enhancing medications.
No takes yet. Share an insight, caveat, or question.
Buchinsky et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: